| scholarly article | Q13442814 |
| P2093 | author name string | Christopher Alexakis | |
| Richard Cg Pollok | |||
| P2860 | cites work | Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 |
| Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? | Q46577284 | ||
| A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization | Q46846798 | ||
| Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. | Q46875109 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort | Q47733622 | ||
| Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. | Q47899983 | ||
| Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. | Q50473979 | ||
| Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. | Q50552144 | ||
| Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study. | Q50562337 | ||
| Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. | Q50788381 | ||
| Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. | Q50898166 | ||
| Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. | Q50988136 | ||
| Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience. | Q51063874 | ||
| An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. | Q51064950 | ||
| The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. | Q51251490 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres | Q57089305 | ||
| Long-term outcome after infliximab for refractory ulcerative colitis | Q57265403 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome | Q59509138 | ||
| The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009 | Q60393803 | ||
| Increasing rates and changing patterns of hospital admissions for patients with inflammatory bowel disease in Ireland: 1996-2001 | Q82416441 | ||
| Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies | Q83836843 | ||
| Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis | Q84490301 | ||
| Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience | Q86456439 | ||
| Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers | Q87490481 | ||
| Rising hospitalization rates for inflammatory bowel disease in Poland | Q87671951 | ||
| Guidelines for the management of inflammatory bowel disease in adults | Q22242049 | ||
| Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis | Q24200757 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT) | Q28657925 | ||
| Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit | Q30664895 | ||
| Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 | ||
| Controlled trial of azathioprine in chronic ulcerative colitis | Q34759169 | ||
| Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis | Q34762742 | ||
| Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials | Q35557586 | ||
| Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. | Q35595821 | ||
| Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis | Q35760789 | ||
| Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis | Q35919991 | ||
| Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. | Q36793930 | ||
| Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis | Q37256032 | ||
| Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care | Q37821792 | ||
| Impact of persistence with infliximab on hospitalizations in ulcerative colitis. | Q37901012 | ||
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management | Q38049776 | ||
| Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis | Q38056807 | ||
| Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis | Q38122070 | ||
| Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies | Q38125012 | ||
| Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis | Q38184706 | ||
| Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor α agents - a systematic review. | Q38274142 | ||
| What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis? | Q42246324 | ||
| Infliximab in the treatment of steroid-dependent ulcerative colitis | Q42644450 | ||
| Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience | Q43496310 | ||
| Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis | Q43700990 | ||
| Decreasing colectomy rates for ulcerative colitis: a population-based time trend study | Q44097483 | ||
| Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 | ||
| Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. | Q44899085 | ||
| Need for hospital admission in patients with ulcerative colitis during maintenance with azathioprine | Q45272078 | ||
| Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis | Q45734256 | ||
| Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. | Q46009898 | ||
| Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis | Q46184125 | ||
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis | Q46286038 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hospitalization | Q3140971 |
| TNF | Q18032037 | ||
| P304 | page(s) | 360-9 | |
| P577 | publication date | 2015-12-27 | |
| P1433 | published in | World journal of gastrointestinal surgery | Q27723330 |
| P1476 | title | Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis | |
| P478 | volume | 7 |
Search more.